These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2906459)

  • 1. Penetration of roxatidine into the cerebrospinal fluid.
    Tryba M; Kurz-Muller K
    Scand J Gastroenterol Suppl; 1988; 146():153-8. PubMed ID: 2906459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.
    Lassman HB; Ho I; Puri SK; Sabo R; Scheffler MR
    Drugs; 1988; 35 Suppl 3():53-64. PubMed ID: 2905250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasma pharmacokinetics of roxatidine in the healthy man: correlation with gastric antisecretory effect].
    Chen WW; Kolsky H; Lewin MJ; Bonfils S
    Gastroenterol Clin Biol; 1990; 14(4):342-6. PubMed ID: 1972124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of roxatidine acetate in patients with chronic liver disease.
    Tsutsumi M; Ueshima Y; Takase S
    J Gastroenterol Hepatol; 2001 Aug; 16(8):910-5. PubMed ID: 11555106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the H(2) blocker roxatidine acetate hydrochloride in pediatric patients, in comparison with healthy adult volunteers.
    Nakamura H; Kawashima H; Azuma R; Sato I; Nagao K; Miyazawa K
    Drug Metab Pharmacokinet; 2012; 27(4):422-9. PubMed ID: 22293541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
    Murdoch D; McTavish D
    Drugs; 1991 Aug; 42(2):240-60. PubMed ID: 1717223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of roxatidine in healthy volunteers.
    Collins JD; Pidgen AW
    Drugs; 1988; 35 Suppl 3():41-7. PubMed ID: 2905248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.
    Lameire N; Rosenkranz B; Brockmeier D
    Scand J Gastroenterol Suppl; 1988; 146():100-10. PubMed ID: 2906455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials.
    Merki HS; Bender W; Labs R
    J Clin Gastroenterol; 1989; 11 Suppl 1():S20-3; discussion S24. PubMed ID: 2572621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency.
    Gladziwa U; Wagner S; Sieberth HG; Klotz U
    Br J Clin Pharmacol; 1995 Feb; 39(2):161-7. PubMed ID: 7742154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of roxatidine acetate on 24-hour gastric acidity. Early evening versus bedtime administration in healthy subjects.
    Hemery P; Congard P; Galmiche JP; Bonfils S
    Drugs; 1988; 35 Suppl 3():76-81. PubMed ID: 2905253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characteristics of roxatidine.
    Bender W; Brockmeier D
    J Clin Gastroenterol; 1989; 11 Suppl 1():S6-19. PubMed ID: 2572622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of multiple dose sucralfate on the pharmacokinetics of of roxatidine acetate.
    Seibert-Grafe M; Pidgen A
    Eur J Clin Pharmacol; 1991; 40(6):637-8. PubMed ID: 1679394
    [No Abstract]   [Full Text] [Related]  

  • 14. A pharmacokinetic study of roxatidine acetate in chronic renal failure.
    Lameire N; Rosenkranz B; Maass L; Brockmeier D
    Drugs; 1988; 35 Suppl 3():48-52. PubMed ID: 2905249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of changing the type of H2-blocker in the treatment of H2-blocker-resistant ulcers: comparison of roxatidine acetate hydrochloride and other H2-blockers.
    Yasutake K; Amano M; Mizokami Y; Kubota S; Fukumoto H; Imamura Y; Yokoya H; Irie K
    J Int Med Res; 1998; 26(1):25-36. PubMed ID: 9513074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceutical characterization of oral controlled/modified-release drug products. In vitro/in vivo correlation of roxatidine.
    Frick A; Möller H; Wirbitzki E
    Eur J Pharm Biopharm; 1998 Nov; 46(3):313-9. PubMed ID: 9885304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacology of histamine H2-receptor antagonists.
    Sewing KF; Beil W; Hannemann H
    Drugs; 1988; 35 Suppl 3():25-9. PubMed ID: 2905246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of roxatidine acetate (HOE-760) on 24-hour intragastric acidity in healthy volunteers: comparison with ranitidine and placebo.
    Merki HS; Witzel L; Kaufmann D; Kempf M; Müssig V; Neumann J; Scheurle E; Röhmel J; Walt RP
    Aliment Pharmacol Ther; 1988 Feb; 2(1):73-81. PubMed ID: 2908751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the animal pharmacology of roxatidine acetate.
    Scholtholt J; Bickel M; Herling AW
    Drugs; 1988; 35 Suppl 3():30-40. PubMed ID: 2905247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of oral administration of roxatidine acetate hydrochloride 3 hours prior to the operation on pH and volume of gastric juice].
    Kojima A; Andoh K; Shima T; Koga Y; Hashimoto Y
    Masui; 1991 Mar; 40(3):451-3. PubMed ID: 1677048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.